Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Innovative Formulation to Enhance Bioavailability and Therapeutic Delivery of Antidiabetics
share announcement

Innovative Formulation to Enhance Bioavailability and Therapeutic Delivery of Antidiabetics

A special issue of Pharmaceutics (ISSN 1999-4923).

Deadline for manuscript submissions: closed (31 August 2019) | Viewed by 6944

Special Issue Editor

Dr. Hani Al-Salami

E-Mail Website
Guest Editor
Biotechnology and Drug Development Research Laboratory, Curtin Medical School & Curtin Health Innovation Research Institute, Curtin University, Kent St, Bentley, WA 6102, Australia
Interests: bile acid nanotechnology; PK/PD; biomaterials; drug commercialization
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

I would like to invite you to submit a publication for consideration in our special issue, in the journal of Pharmaceutics (impact factor 3.7, Q1 ranked), entitled: Innovative Formulation to Enhance Bioavailability and Therapeutic Delivery of antidiabetics.

The publication needs to address scientific questions in the areas of drug delivery, targeted-delivery, pharmacokinetic and pharmacodynamic optimization and formulation-enhancement to optimise drug pharmacological efficacy and safety profiles.

The focus of the research needs to be on using novel and cutting-edge bio-nanotechnologies and microfluidic and microchip delivery systems to potentially deliver drugs and optimise their effectiveness and safety profiles. The research can also include using off-the-shelf and synthetic smart polymers in drug encapsulation and tissue-targeted deliveries, peptide-functionalization technologies, and transplantable medical devices, in controlling drug delivery mechanisms.

Dr. Hani Al-Salami
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes treatment
  • drug targeted-delivery
  • bio-nanotechnology
  • drug pharmacokinetic
  • pharmacodynamic properties

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 1847 KiB  
Article
Effective Therapeutic Delivery and Bioavailability Enhancement of Pioglitazone Using Drug in Adhesive Transdermal Patch
by Anroop B. Nair, Sumeet Gupta, Bandar E. Al-Dhubiab, Shery Jacob, Pottathil Shinu, Jigar Shah, Mohamed Aly Morsy, Nagaraja SreeHarsha, Mahesh Attimarad, Katharigatta N. Venugopala and Sabah H. Akrawi
Pharmaceutics 2019, 11(7), 359; https://doi.org/10.3390/pharmaceutics11070359 - 23 Jul 2019
Cited by 29 | Viewed by 6365
Abstract
The administration of pioglitazone as an oral therapy is restricted due to various challenges. The aim of the current investigation was to evaluate the suitability of pioglitazone in adhesive transdermal patch as an alternative delivery system, in order to improve therapeutic delivery. Drug [...] Read more.
The administration of pioglitazone as an oral therapy is restricted due to various challenges. The aim of the current investigation was to evaluate the suitability of pioglitazone in adhesive transdermal patch as an alternative delivery system, in order to improve therapeutic delivery. Drug in adhesive pioglitazone (2% w/w) transdermal patch were optimized for drug release, suitable adhesive, and skin permeation enhancer. The selected patch was examined for drug-loading capacity and the patch with greater pioglitazone (6% w/w) was evaluated in rat models. The release of pioglitazone was influenced by the tested adhesive and was shown to be significantly higher (p < 0.001) with patch, prepared using Duro-Tak 87-2516. The ex vivo permeation results substantiate the release data as a greater transdermal flux (15.67 ± 2.35 µg/cm2/h) was demonstrated in patch fabricated with Duro-Tak 87-2516. Skin penetration enhancers promoted the ex vivo transdermal delivery of pioglitazone, and was ~2 folds (p < 0.0001) higher with propylene glycol, as compared to patch without enhancer. The maximum solubility of pioglitazone in Duro-Tak 87-2516 was found to be 6% w/w. Increasing the drug content in patch enhanced the transdermal flux and was highest when the pioglitazone level was 6% w/w (72.68 ± 5.76 µg/cm2/h). In vivo pharmacokinetic data demonstrate that the AUC0-α in transdermal application (13,506.51 ± 1649.92 ng·h/mL) was ~2 times higher (p < 0.0001) as compared to oral dosage form. In conclusion, the promising results observed here signifies that developed patch could be a viable alternative for oral therapy of pioglitazone. Full article
(This article belongs to the Special Issue Innovative Formulation to Enhance Bioavailability and Therapeutic Delivery of Antidiabetics)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop